Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585975 | 0.96 | GRM2 (0.92) | GRM2HTR2CALDH1A1STAT3SCN5A | |
| SCHEMBL1003316 | 0.92 | GRM2 (0.85) | GRM2ALDH1A1TSHRSTAT3SCN5A | |
| SCHEMBL2023554 | 0.92 | GRM2 (0.84) | GRM2ALDH1A1TSHRSTAT3SCN5A | |
| SCHEMBL1000992 | 0.89 | GRM2 (0.81) | GRM2ALDH1A1TSHRSTAT3SCN5A | |
| SCHEMBL2123824 | 0.88 | GRM2 (0.78) | GRM2ALDH1A1KCNH2PLAT | |
| SCHEMBL30789127 | 0.88 | GRM2 (0.78) | GRM2ALDH1A1KCNH2PLAT | |
| SCHEMBL2022166 | 0.88 | GRM2 (0.78) | GRM2HTR2CALDH1A1SCN5ATYMS | |
| SCHEMBL1005072 | 0.86 | GRM2 (0.76) | GRM2ALDH1A1STAT3SCN5APHGDH | |
| SCHEMBL2122976 | 0.86 | GRM2 (0.76) | GRM2HTR2CALDH1A1TSHRSTAT3 | |
| SCHEMBL2025577 | 0.86 | GRM2 (0.75) | GRM2HTR2CALDH1A1TSHRSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050427-A1 | TREATMENTS FOR OBSESSIVE COMPULSIVE DISORDER | SIRGARTAN HOLDINGS LTD (GB) | 2024-02-15 | — | — | US | claimed |
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | claimed |
| EP-2444399-B1 | Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators | ASTRAZENECA AB (SE) | 2014-11-26 | — | — | EP | claimed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2167502-B3 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2013-07-10 | — | — | EP | claimed |
| US-8377940-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | claimed |
| US-8377939-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | claimed |
| EP-2521722-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | AstraZeneca AB (SE) | 2012-11-14 | — | — | EP | claimed |
| EP-2167502-B1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2012-09-19 | — | — | EP | claimed |
| WO-2011084098-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2011-07-14 | — | — | WO | claimed |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | claimed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| US-20250376518-A1 | Anti-mGluR2 Biparatopic Nanobodies and Uses Thereof | UNIVERSITE DE MONTPELLIER (FR) | 2025-12-11 | — | — | US | disclosed |
| US-20250288584-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-18 | — | — | US | disclosed |
| EP-4547332-A1 | ANTI-MGLUR2 BIPARATOPIC NANOBODIES AND USES THEREOF | UNIVERSITE DE MONTPELLIER (FR) | 2025-05-07 | — | — | EP | disclosed |
| US-20250041301-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-06 | — | — | US | disclosed |
| WO-2008150233-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050427-A1 | TREATMENTS FOR OBSESSIVE COMPULSIVE DISORDER | HCRTR1, HCRTR2, TAAR5 | GRM2 139/4885HTR2C 7/4885ALDH1A1 357/4885 |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | GRM1, GRIN1, GRM2 | GRM2 3/4885HTR2C 172/4885ALDH1A1 1079/4885 |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | GRM4, GRIK4, GRIA4 | GRM2 6/4885HTR2C 122/4885ALDH1A1 3129/4885 |
| US-20250288584-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2C 59/4885ALDH1A1 4650/4885 |
| US-20250041301-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2C 59/4885ALDH1A1 4650/4885 |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | GRM1, GRM2, GRIN1 | GRM2 2/4885HTR2C 199/4885ALDH1A1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.